Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed compelling molecular responses in patients with heavily pre-treated CML, including deepening responses in patients with poor response to asciminib Additional safety and efficacy data from CARDINAL, including 6-month major molecular response (MMR) rates expec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Delaware 98-1448275 (State or other jurisdiction of incorporation or organization) 1065 East Hillsdale Blvd., Suite 100 Foster City, California 94404 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identificat ...

Exhibit 99.1 Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER CITY, Calif., May 8, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinica ...

Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serio ...

Summary of Terns Pharmaceuticals (TERN) Conference Call Company Overview - **Company**: Terns Pharmaceuticals (TERN) - **Date of Conference**: May 07, 2025 - **Key Speakers**: Scott Harris (Chief Development Officer), Andrew Gragos (Chief Financial Officer) Key Points on Oncology and CML - **Unmet Need in CML**: Chronic Myeloid Leukemia (CML) treatment has evolved since the introduction of Gleevec in 2001, but there remains a need for improved efficacy and safety in treatments [6][7] - **Introduction of TURN701**: TURN701 is positioned as a potential best-in-class allosteric TKI for CML, showing preclinical potency greater than Novartis' Osimhenib and improved pharmacokinetics [8][12] - **Safety and Tolerability**: TURN701 has demonstrated no dose-limiting toxicities in trials, lacks significant drug-drug interactions, and is not an inhibitor of CYP3A4, which is crucial for patient safety [10][11] - **Patient Convenience**: TURN701 is a once-daily medication with no clinically meaningful food effect, contrasting with Osimhenib, which requires fasting [11][12] - **Switching Rates**: Up to 50% of patients on active site TKIs switch treatments within the first year, primarily due to suboptimal response or tolerability issues [14][15] - **Early Clinical Data**: In a phase one study, a 50% cumulative Major Molecular Response (MMR) rate was observed at three months among evaluable patients, with no significant adverse effects reported [17][18][22] Key Points on TURN601 (Oral GLP-1) - **Overview of TURN601**: An orally available GLP-1 receptor agonist, with initial studies showing weight loss of up to 5.5% at the highest dose over 28 days [28][35] - **Tolerability Profile**: TURN601 is designed to have a favorable tolerability profile, with rapid absorption and less central nervous system liability [30][31] - **Comparison with Competitors**: The discontinuation of Pfizer's Donluplin does not pose a direct risk to TURN601, as it has distinct pharmaceutical properties [32][33] - **Ongoing Studies**: A twelve-week study is currently enrolling, with expectations for data release in Q4 2025 [28][44] - **Market Positioning**: The company aims to establish partnerships for TURN601, given the high costs associated with obesity drug development [47][48] Additional Insights - **Market Dynamics**: The presence of multiple players in the obesity market is seen as beneficial for patient access and treatment options [52][53] - **Patient Segmentation**: There is a shift in focus towards gradual weight loss and tolerability, appealing to a broader patient population [58][59] - **Future Directions**: The company is optimistic about the potential for TURN701 and TURN601 to establish themselves in their respective markets, with ongoing studies and data expected to support their claims [54][56]

FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET. A live webcast of the fireside chat will be av ...

A downtrend has been apparent in Terns Pharmaceuticals, Inc. (TERN) lately with too much selling pressure. The stock has declined 39.8% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical in ...

A downtrend has been apparent in Terns Pharmaceuticals, Inc. (TERN) lately with too much selling pressure. The stock has declined 31.4% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical ...

FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Comp ...

Terns Pharmaceuticals, Inc. (TERN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...